GBIO Generation Bio Co. Stock Quote

GBIO [NASD]

Index	-	P/E	-	EPS (ttm)	-1.66	Insider Own	20.10%	Shs Outstand	48.49M	Perf Week	-15.42%
Market Cap	1.68B	Forward P/E	-	EPS next Y	-1.87	Insider Trans	-5.62%	Shs Float	36.15M	Perf Month	10.88%
Income	-80.50M	PEG	-	EPS next Q	-0.45	Inst Own	82.00%	Short Float	12.24%	Perf Quarter	-12.58%
Sales	-	P/S	-	EPS this Y	-63.70%	Inst Trans	6.57%	Short Ratio	9.19	Perf Half Y	14.03%
Book/sh	5.53	P/B	5.45	EPS next Y	2.10%	ROA	-30.10%	Target Price	43.33	Perf Year	-
Cash/sh	4.70	P/C	6.41	EPS next 5Y	-	ROE	-43.30%	52W Range	17.00 - 55.72	Perf YTD	6.38%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-45.87%	Beta	-
Dividend %	-	Quick Ratio	23.90	Sales past 5Y	-	Gross Margin	-	52W Low	77.41%	ATR	2.36
Employees	100	Current Ratio	23.90	Sales Q/Q	-	Oper. Margin	-	RSI (14)	42.85	Volatility	9.19% 7.68%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	53.00%	Profit Margin	-	Rel Volume	0.56	Prev Close	32.36
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Mar 18 BMO	Payout	-	Avg Volume	481.36K	Price	30.16
Recom	1.50	SMA20	-6.79%	SMA50	-7.07%	SMA200	-0.43%	Volume	271,408	Change	-6.80%

Feb-24-21

Initiated

William Blair

Outperform

Feb-18-21

Initiated

Needham

Buy

$50

Jul-07-20

Initiated

Wedbush

Outperform

$31

Jul-07-20

Initiated

JP Morgan

Overweight

$28

Jul-07-20

Initiated

Jefferies

Buy

$38

Jul-07-20

Initiated

Cowen

Outperform

Apr-27-21 04:35PM	Generation Bio to Present at American Society of Gene & Cell Therapy 2021 Virtual Annual Meeting GlobeNewswire
Apr-08-21 07:30AM	Generation Bio to Present at 20th Annual Needham Virtual Healthcare Conference GlobeNewswire
Mar-21-21 05:20AM	Could The Generation Bio Co. (NASDAQ:GBIO) Ownership Structure Tell Us Something Useful? Simply Wall St.
Mar-18-21 08:00AM	Generation Bio Reports Fourth Quarter and Full Year 2020 Financial Results GlobeNewswire
Mar-01-21 08:53AM	Why Earnings Season Could Be Great for Generation Bio (GBIO) Zacks +15.12%
Feb-18-21 10:02AM	Benzinga's Top Ratings Upgrades, Downgrades For February 18, 2021 Benzinga
07:30AM	Generation Bio Appoints Ron Cooper to Its Board of Directors GlobeNewswire
Jan-13-21 11:29PM	Trade Alert: The Independent Director Of Generation Bio Co. (NASDAQ:GBIO), Charles Rowland, Has Just Spent US$500k Buying 25% More Shares Simply Wall St.
Jan-11-21 05:43PM	Generation Bio Announces Closing of Public Offering GlobeNewswire
Jan-06-21 09:24PM	Generation Bio Announces Pricing of Public Offering GlobeNewswire
Jan-05-21 08:44AM	Generation Bio (GBIO) Catches Eye: Stock Jumps 6.1% Zacks -17.22%
06:30AM	Generation Bio to Present at 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-04-21 06:30AM	Generation Bio Announces Two Non-Viral Gene Therapy Milestone Achievements: Target Levels of Factor VIII Expression in Hemophilia A Mice and Translation of Expression from Mice to Non-Human Primates GlobeNewswire +6.10%
Dec-13-20 03:52AM	Need To Know: Generation Bio Co. (NASDAQ:GBIO) Insiders Have Been Buying Shares Simply Wall St.
Dec-02-20 11:34PM	Is Generation Bio (GBIO) A Good Stock To Buy Now? Insider Monkey +6.59%
Nov-10-20 06:30AM	Generation Bio Reports Third Quarter 2020 Business Updates and Financial Results GlobeNewswire
Oct-31-20 08:00AM	Kaskela Law LLC Announces Stockholder Investigation of Generation Bio Co. - GBIO ACCESSWIRE
Oct-05-20 06:30AM	Generation Bio to Present at 2020 Virtual Cell & Gene Meeting on the Mesa GlobeNewswire +7.22%
Sep-24-20 06:30AM	Generation Bio to Present at the Jefferies 2020 Virtual Gene Therapy/Editing Summit GlobeNewswire
Sep-14-20 10:59AM	Generation Bio (NASDAQ:GBIO) Is In A Good Position To Deliver On Growth Plans Simply Wall St. +7.90%
Aug-11-20 06:30AM	Generation Bio Reports Business Updates and Second Quarter 2020 Financial Results GlobeNewswire
Aug-05-20 06:30AM	Generation Bio to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference GlobeNewswire
Jul-22-20 07:00AM	Generation Bio Appoints Matthew Norkunas, M.D., MBA as Chief Financial Officer GlobeNewswire
Jun-16-20 04:02PM	Generation Bio Announces Closing of Initial Public Offering GlobeNewswire -12.15%
Jun-12-20 12:31PM	Generation Bio shares soar 23% in trading debut MarketWatch
06:24AM	Generation Bio prices upsized IPO at $19 a share to raise $199.5 million MarketWatch
Jun-11-20 09:52PM	Generation Bio Announces Pricing of Initial Public Offering GlobeNewswire

Generation Bio Co., a genetic medicines company, develops gene therapies for the treatment of rare and prevalent diseases. The company is developing a portfolio of programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MCDONOUGH GEOFF	PRESIDENT AND CEO	Apr 23	Sale	35.10	10,000	351,000	1,184,080	Apr 27 04:02 PM
Zimmermann Tracy	CHIEF DEVELOPMENT OFFICER	Apr 22	Option Exercise	4.59	2,500	11,475	2,500	Apr 23 04:05 PM
Stanton Matthew	CHIEF SCIENTIFIC OFFICER	Apr 22	Option Exercise	0.60	1,500	900	199,654	Apr 23 04:05 PM
Stanton Matthew	CHIEF SCIENTIFIC OFFICER	Apr 22	Sale	34.03	1,500	51,045	198,154	Apr 23 04:05 PM
Zimmermann Tracy	CHIEF DEVELOPMENT OFFICER	Apr 22	Sale	33.32	2,500	83,300	0	Apr 23 04:05 PM
Stanton Matthew	CHIEF SCIENTIFIC OFFICER	Apr 21	Option Exercise	0.60	1,500	900	199,654	Apr 23 04:05 PM
Stanton Matthew	CHIEF SCIENTIFIC OFFICER	Apr 21	Sale	31.07	1,500	46,605	198,154	Apr 23 04:05 PM
Stanton Matthew	CHIEF SCIENTIFIC OFFICER	Apr 16	Option Exercise	0.60	1,500	900	199,654	Apr 20 04:05 PM
Stanton Matthew	CHIEF SCIENTIFIC OFFICER	Apr 16	Sale	28.03	1,500	42,045	198,154	Apr 20 04:05 PM
Rhodes Jason P	Director	Apr 14	Sale	26.61	23,413	622,995	0	Apr 14 08:20 PM
ATLAS VENTURE ASSOCIATES X, L.	10% Owner	Apr 14	Sale	26.61	23,413	622,995	0	Apr 14 08:19 PM
Rhodes Jason P	Director	Apr 13	Sale	25.16	43,145	1,085,744	23,413	Apr 14 08:20 PM
ATLAS VENTURE ASSOCIATES X, L.	10% Owner	Apr 13	Sale	25.16	43,145	1,085,744	23,413	Apr 14 08:19 PM
Stanton Matthew	CHIEF SCIENTIFIC OFFICER	Apr 12	Option Exercise	0.60	6,000	3,600	204,154	Apr 14 04:01 PM
Rhodes Jason P	Director	Apr 12	Sale	26.15	74,124	1,938,229	66,558	Apr 14 08:20 PM
ATLAS VENTURE ASSOCIATES X, L.	10% Owner	Apr 12	Sale	26.15	74,124	1,938,229	66,558	Apr 14 08:19 PM
Stanton Matthew	CHIEF SCIENTIFIC OFFICER	Apr 12	Sale	26.24	6,000	157,446	198,154	Apr 14 04:01 PM
ATLAS VENTURE ASSOCIATES X, L.	10% Owner	Apr 09	Sale	27.61	43,681	1,205,948	140,682	Apr 09 08:54 PM
Rhodes Jason P	Director	Apr 09	Sale	27.61	43,681	1,205,948	140,682	Apr 09 08:53 PM
ATLAS VENTURE ASSOCIATES X, L.	10% Owner	Apr 08	Sale	28.50	43,550	1,241,241	184,363	Apr 09 08:54 PM
Rhodes Jason P	Director	Apr 08	Sale	28.50	43,550	1,241,241	184,363	Apr 09 08:53 PM
ATLAS VENTURE ASSOCIATES X, L.	10% Owner	Apr 07	Sale	28.51	39,864	1,136,671	227,913	Apr 09 08:54 PM
Rhodes Jason P	Director	Apr 07	Sale	28.51	39,864	1,136,671	227,913	Apr 09 08:53 PM
Kerr Douglas	CHIEF MEDICAL OFFICER	Apr 05	Option Exercise	5.16	14,072	72,612	340,630	Apr 07 04:05 PM
Kerr Douglas	CHIEF MEDICAL OFFICER	Apr 05	Sale	30.09	14,072	423,451	326,558	Apr 07 04:05 PM
Stanton Matthew	CHIEF SCIENTIFIC OFFICER	Mar 10	Option Exercise	0.60	10,500	6,300	208,654	Mar 12 04:03 PM
Stanton Matthew	CHIEF SCIENTIFIC OFFICER	Mar 10	Sale	34.97	10,500	367,210	198,154	Mar 12 04:03 PM
Kerr Douglas	CHIEF MEDICAL OFFICER	Mar 05	Option Exercise	4.59	11,267	51,716	337,825	Mar 09 04:05 PM
Kerr Douglas	CHIEF MEDICAL OFFICER	Mar 05	Sale	31.44	11,267	354,267	326,558	Mar 09 04:05 PM
Zimmermann Tracy	CHIEF DEVELOPMENT OFFICER	Mar 03	Option Exercise	4.59	3,000	13,770	3,000	Mar 05 04:05 PM
Zimmermann Tracy	CHIEF DEVELOPMENT OFFICER	Mar 03	Sale	41.38	3,000	124,140	0	Mar 05 04:05 PM
Zimmermann Tracy	CHIEF DEVELOPMENT OFFICER	Mar 01	Option Exercise	4.59	2,500	11,475	2,500	Mar 03 04:10 PM
Zimmermann Tracy	CHIEF DEVELOPMENT OFFICER	Mar 01	Sale	38.84	2,500	97,099	0	Mar 03 04:10 PM
MCDONOUGH GEOFF	PRESIDENT AND CEO	Mar 01	Sale	37.58	10,000	375,801	1,194,080	Mar 03 04:10 PM
Stanton Matthew	CHIEF SCIENTIFIC OFFICER	Feb 10	Option Exercise	0.60	10,400	6,240	208,554	Feb 12 04:05 PM
Stanton Matthew	CHIEF SCIENTIFIC OFFICER	Feb 10	Sale	34.60	10,400	359,856	198,154	Feb 12 04:05 PM
Kerr Douglas	CHIEF MEDICAL OFFICER	Feb 08	Option Exercise	4.59	11,267	51,716	337,825	Feb 10 04:05 PM
Kerr Douglas	CHIEF MEDICAL OFFICER	Feb 08	Sale	33.37	11,267	375,954	326,558	Feb 10 04:05 PM
Zimmermann Tracy	CHIEF DEVELOPMENT OFFICER	Feb 02	Option Exercise	4.59	2,500	11,475	2,500	Feb 04 04:05 PM
Zimmermann Tracy	CHIEF DEVELOPMENT OFFICER	Feb 02	Sale	33.05	2,500	82,625	0	Feb 04 04:05 PM
Angelino Mark D.	CHIEF OPERATING OFFICER	Jan 15	Option Exercise	4.59	7,500	34,425	353,137	Jan 20 04:05 PM
Angelino Mark D.	CHIEF OPERATING OFFICER	Jan 15	Sale	32.97	7,500	247,273	345,637	Jan 20 04:05 PM
Stanton Matthew	CHIEF SCIENTIFIC OFFICER	Jan 14	Option Exercise	0.60	5,630	3,378	203,784	Jan 15 04:05 PM
Zimmermann Tracy	CHIEF DEVELOPMENT OFFICER	Jan 14	Option Exercise	4.59	2,500	11,475	2,500	Jan 15 04:06 PM
Zimmermann Tracy	CHIEF DEVELOPMENT OFFICER	Jan 14	Sale	33.09	2,500	82,725	0	Jan 15 04:06 PM
Stanton Matthew	CHIEF SCIENTIFIC OFFICER	Jan 14	Sale	32.54	5,630	183,212	198,154	Jan 15 04:05 PM
Kerr Douglas	CHIEF MEDICAL OFFICER	Jan 11	Option Exercise	4.59	11,267	51,716	337,825	Jan 13 04:07 PM
Stanton Matthew	CHIEF SCIENTIFIC OFFICER	Jan 11	Option Exercise	0.60	14,820	8,892	212,974	Jan 13 04:06 PM
Rowland Charles A Jr	Director	Jan 11	Buy	24.50	20,408	499,996	101,035	Jan 13 04:04 PM
Nicholson Donald William	Director	Jan 11	Buy	24.50	4,081	99,984	103,157	Jan 13 04:05 PM
Kerr Douglas	CHIEF MEDICAL OFFICER	Jan 11	Sale	27.58	11,267	310,768	326,558	Jan 13 04:07 PM
Stanton Matthew	CHIEF SCIENTIFIC OFFICER	Jan 11	Sale	27.69	14,820	410,372	198,154	Jan 13 04:06 PM
Angelino Mark D.	Chief Operating Officer	Dec 15	Option Exercise	4.59	5,301	24,332	350,938	Dec 17 04:05 PM
Angelino Mark D.	Chief Operating Officer	Dec 15	Sale	34.98	5,301	185,431	345,637	Dec 17 04:05 PM
Stanton Matthew	Chief Scientific Officer	Dec 10	Option Exercise	0.60	10,540	6,324	208,694	Dec 14 04:05 PM
Stanton Matthew	Chief Scientific Officer	Dec 10	Sale	37.62	10,540	396,499	198,154	Dec 14 04:05 PM
Angelino Mark D.	Chief Operating Officer	Aug 14	Option Exercise	0.60	62,560	37,536	345,637	Aug 18 04:07 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience